Literature DB >> 29729781

Radiation for Treatment of Painful Bone Metastases.

Ron Shiloh1, Monica Krishnan2.   

Abstract

Several variables may be considered when deciding on optimal modality of radiation therapy for each cancer patient with bone pain, including prognosis, tumor histology, location and extent of metastases, and association with cord compression. Hypofractionated external beam radiation therapy is as effective as a multiple fraction radiotherapy course in most cases, although retreatment rates are higher after a single dose of radiation. Stereotactic body radiation may be used in cases of oligometastatic disease, repeat irradiation, and radiation-resistant tumors. Radiopharmaceuticals may be used for pain from diffuse bone metastases and have an overall survival benefit in patients with castrate-resistant prostate cancer.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone metastases; External beam radiation therapy; Hypofractionation; Radiopharmaceuticals; Stereotactic body radiation therapy

Mesh:

Year:  2018        PMID: 29729781     DOI: 10.1016/j.hoc.2018.01.008

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  3 in total

1.  Palliative Radiation Therapy for Bone Metastases in Neuroendocrine Neoplasms.

Authors:  Michelle Guan; Ingrid He; Michael Luu; John David; Jun Gong; Veronica R Placencio-Hickok; Robert S Reznik; Richard Tuli; Andrew E Hendifar
Journal:  Adv Radiat Oncol       Date:  2019-04-10

Review 2.  Biological and Clinical Aspects of Metastatic Spinal Tumors.

Authors:  Jakub Litak; Wojciech Czyżewski; Michał Szymoniuk; Leon Sakwa; Barbara Pasierb; Joanna Litak; Zofia Hoffman; Piotr Kamieniak; Jacek Roliński
Journal:  Cancers (Basel)       Date:  2022-09-22       Impact factor: 6.575

Review 3.  Radiation therapy for oligometastatic bone disease in breast cancer.

Authors:  Norihisa Katayama; Kuniaki Katsui; Kenta Watanabe; Ryota Nagao; Kaho Otsuki; Takao Hiraki; Susumu Kanazawa
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.